ArticleNeuroprotection (Chichester, England)2026
Post-Omicron cognitive decline is largely reversible: Two-year multicenter cohort study of domain-specific outcomes in hospitalized patients.
Article in Neuroprotection (Chichester, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Post-Omicron cognitive decline is largely reversible: Two-year multicenter cohort study of domain-specific outcomes in hospitalized patients.Neuroprotection (Chichester, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cognitive impairment represents a significant concern within the spectrum of post-acute sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, particularly impacting the aging population. This study aimed to assess the incidence of reversible and irreversible cognitive decline after Omicron infection, identify changes in specific cognitive domains, and determine the risk factors for progressive cognitive decline. Methods: In this multicenter longitudinal cohort, 3419 patients diagnosed with Coronavirus Disease 2019 (COVID-19) between December 2022 and March 2023 from nine hospitals in China were enrolled. Cognitive function was assessed at 6 months and 2 years post-infection using the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) and Telephone Interview of Cognitive Status-40 (TICS-40). Domain-specific performance was analyzed, and logistic regression was used to identify risk factors. Results: In total, 2087 patients with COVID-19 completed both the 6-month and 2-year follow-up (1172 [56.2%] men; 915 [43.8%] women; median age 63.0 years [interquartile range]: 53.0-71.0) respectively. Two years after discharge from the hospital, 67.1% (1401/2087) of survivors maintained stable cognitive function, 22.0% (460/2087) of survivors experienced reversible cognitive decline, and 10.8% (226/2087) experienced irreversible cognitive decline (3.6% [76/2087] showed progressive cognitive decline). The profile of recovery or deterioration in cognitive domains involved attention/calculation, executive function, delayed recall, registration, and learning, all of which are multi-dimensional. Age ≥60 years (OR = 4.31, 95% CI [1.47, 12.65]), reinfection (OR = 2.12, 95% CI [1.33, 3.38]), and vaccination doses (OR = 0.69, 95% CI [0.55, 0.87]) were associated with progressive decline. Conclusion: Post-Omicron cognitive decline is largely reversible, with significant recovery observed in key domains including attention/calculation, executive function, delayed recall, registration, and learning. However, a vulnerable subset with risk factors such as older adults, reinfection, and inadequate vaccination, is at risk for progressive cognitive decline. These findings highlight the necessity of targeted long-term monitoring and early intervention for high-risk populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.